The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer

Abiraterone and enzalutamide significantly increase the incidence and RR of cardiovascular toxicity in patients affected by metastatic prostate cancer. Follow-up for the onset of treatment-related cardiovascular events should therefore be considered in these patients.